



# **Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016**

**Weekending:- 05-01-2018**

**Legal Publication Date:- 19-01-2018**

**Journal Code (180119)**

**NEW APPLICATIONS FOR THE PATENTS**

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

<b>02-01-2018</b>		
01/2018	Dr. Muhammad Athar Abbasi Dr. Khalid Mohammad Khan Dr. Aziz-ur-Rehman Dr. Abdul Hameed Dr. Sabahat Zahra Siddiqui Dr. Muahmmad Ashraf Pakistan	“VALUABLE TYPE II DIABETES ENTRANT: N-(2,3-DIMETHYLPHENYL)-4-[(2,4-DICHLORO-6-([4-(2-FUROYL)-1-PIPERAZINYL]SULFONYL} PHENOXY) METHYL}BENZAMIDE”
02/2018	Dr. Muhammad Athar Abbasi Dr. Khalid Mohammad Khan Dr. Aziz-ur-Rehman Dr. Abdul Hameed Dr. Sabahat Zahra Siddiqui Dr. Muahmmad Ashraf Pakistan	“A POTENT TARGET FOR THE TREATMENT OF TYPE 2 DIABETES N-(5-CHLORO-2-METHOXYPHENYL)-2-({5-[3-(1H-INDOL-3-YL) PROPYL]-1,3,4-OXADIAZOL-2-YL} SULFONYL} ACETAMIDE”
03/2018	M/s. Kanzo Ag, Multan – Pakistan	“Water-Dispersible Granules (WDG) Herbicide Formulation from Clopyralid, Fluroxypyr-meptyl and Tribenuron-methyl and Process of Preparation thereof”
04/2018	M/s. Kanzo Ag, Multan – Pakistan	“Emulsifiable Composition if Water-Insoluble Herbicide from Fluroxypyr-meptyl, MCPA and Clopyralid Process of Preparation thereof”
05/2018	VIIV HEALTHCARE UK (No.5) LIMITED United Kingdom (Priority 03-01-2017 US)	“PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION”
06/2018	Prof. Dr. Majid Mumtaz Department of Chemistry, University of Karachi	“A Method for sharing the burden of freshwater resources in irrigation by treatment wastewater”

	Karachi – Pakistan	
07/2018	BAYER AKTIENGESELLSCHAFT Germany BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 10-01-2017 EP)	“HETEROCYCLE DERIVATIVES AS PESTICIDES”
08/2018	BAYER AKTIENGESELLSCHAFT Germany BAYER CROPSCIENCE AKTIENGESELLSCHAFT Germany (Priority 10-01-2017 EP)	“HETEROCYCLE DERIVATIVES AS PESTICIDES”
<b>03-01-2018</b>		
09/2017	Dr. Sadia Ajaz Ms. Sani-e-Zehra Ms. Saleema Mehboob Ali Karachi – Pakistan	“DETECTION OF FAMILIAL BREAST CENCERS CAUSED BY BRCA2 c.5642delAATC MUTATION”
<b>04-01-2018</b>		
10/2018	SICPA HOLDING SA, Switzerland (Priority 05-01-2017 EP)	“METHOD FOR MANAGING A PRODUCTION LINE”
11/2018	LES LABORATOIRES SERVIER FRANCE NOVARTIS AG SWITZERLAND (Priority 06-01-2017 US)	“COMBINATION OF AMCL-1 INHIBITOR AND A TAXANE COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF”
<b>05-01-2018</b>		
12/2018	PHARMACYCLICS, LLC USA (Priority 06-01-2017 US)	“PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE”

**APPLICATION ACCEPTED**

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

<p>428/2006</p>	<p>BP Corporation North America Inc., U.S.A.</p>	<p>" A process for energy recovery during the production of aromatic carboxylic acid by liquid phase oxidation of aromatic hydrocarbon"</p> <p>C07C51/256,C07C63/15 &amp; B01D03/14.</p> <p style="text-align: right;"><b>142651</b></p> <p>Energy is recovered during the production of aromatic carboxylic acids by liquid phase oxidation of aromatic hydrocarbons by performing a high efficiency separation on the reactor overhead vapor to form a high pressure gaseous overhead stream comprising water and organic impurities; recovering heat energy from the high pressure gaseous overhead stream by exchanging heat with a suitable heat sink material such that a condensate comprising from about 20 wt% to about 60 wt% of the water present in the high pressure gaseous overhead stream is formed and a high pressure off-gas is formed; and recovering</p>
-----------------	--	---

		energy in the form of work from the high pressure off-gas. Preferably such work is recovered using isentropic means for energy recovery, for example an expander. Apparatus for such process is also provided.
113/2012	<p>1) Dr. Mohammad A. Khan,                  2) Mr. Mohammad Arif.                  3) Dr. Imtiaz-ud-Din.                  4) Dr. Khalid Mohammad Khan.                  5) Dr. Nida. Ambreen                  6) Dr. Shahnaz Perveen Pakistan.</p>	<p>"A process for the extraction of phosphoric acid by amyl alcohol"</p> <p>C01B25/22.</p> <p style="text-align: right;"><b>142652</b></p> <p>A process describes an efficient and economical route for the preparation of phosphoric acid by treating rock phosphate with commercial hydrochloric acid which is a cheap by-product of the soda ash industries followed by its separation from the crude mixture by solvent extraction using amyl alcohol as solvent to remove impurities up to a great extent and yields phosphoric acid of good quality which easily concentrates. The recovery of the amyl alcohol from different stages of the process is found to be convenient due to its low water miscibility, and its re-extraction efficiency is comparable to that of fresh solvent, the alcohol easily recover from the raffinate phase by vacuum distillation at 110 °C. Maximum phosphorous pentaoxide (P<sub>2</sub>O<sub>5</sub>) is recovered when an acid-rock ratio is 1:1.2 w/v and acid /alcohol ratio is kept at 1:2 and extraction efficiency reaches a maximum of 65%. The addition of small amounts of acetaldehyde increases the extraction efficiency from 41 to 65%. The acid, obtained by this metho is of high quality and could be upgraded up to density of 1.5 g/mL at 25 °C, it is an efficient and economical method.</p>
161/ 2012	CHIESI FARMACEUTICI S.P.A., Italy.	<p>" ISOXAZOLIDINE COMPOUND"</p> <p>C07J71/00,A61K31/58,A61P5/44,A61P11/06 &amp; A61P37/08.</p>

		<p style="text-align: right;"><b>142653</b></p> <p>The present invention relates to novel anti-inflammatory and antiallergic compound of the general formula (I) (As Annexed) of the glucocorticosteroid series, wherein  <math>R_1 - (CH_2)_n - Z - (CH_2)_{n'} - R_3</math> wherein n and n' are each independently 0, 1 or 2;  Z is a single bond or is selected from —S—, —O— and —OC(R<sub>4</sub>R<sub>5</sub>)—; R<sub>2</sub> and R<sub>3</sub> as defined therein; X and Y are independently H or halogen;  method of preparing such compound, pharmaceutical composition comprising them, and combination thereof.</p>
<p>326/2012</p>	<p>1) Engr. Muhammad Ashraf. Pakistan. 2) Farid Ahmed Yasin. Pakistan. 3) Syed Faisal Imam. Pakistan. 4) Khalid Saleem Khan. Pakistan. 5) Ali Sultan. Pakistan.</p>	<p>"A SYSTEM FOR THE PURIFICATION OF BIOGAS"  A61K31/00.</p> <p style="text-align: right;"><b>142654</b></p> <p>The present invention is a biogas purification system, which uses a novel method for the complete removal of traces of hydrogen sulfide and water vapors as well as the removal of more than 90% of carbon dioxide from biogas.  The said system comprises of an apparatus which is connected with Digester (source of Biogas to be purified), started with Chamber 1 (C1), vessel (V) containing solution (mixture of mono ethanol amine and di ethanol amine) and Chamber 2 (C2). These all three stages are connected through pipes in series. This sequence provides the sorbents present in each stage a strong environment to react with desired impurity. A Positive displacement compressor is in downstream which is connected with apparatus on its inlet and with storage tank on its outlet. The vessel (V) has three "control valve loaded" pipe connections at the bottom for Gas entrance, emerging entrance pipe (if return valve chokes) and drain pipe, respectively. The vessel also has a loading pipe for solution (mixture of mono ethanol amine and di ethanol amine), a pressure gauge a safety valve</p>

		<p>and an outlet pipe (for CO<sub>2</sub> while recovering it with simultaneous regeneration of chemical mixture) at the top thereof. The internal surface of said apparatus used in the said system including that of the connecting pipes is PVC coated whereas the material of external construction is SS 316. The whole apparatus has the same metallic assembly which fixes all stages on the same plate. It could be a fixed apparatus or mobile apparatus. Any option can be used according to requirements.</p> 
<p>676/ 2012</p>	<p>AMERICAN PACIFIC CORPORATION, U.S.A.</p>	<p>" A fire extinguishing composition comprising a bromofluorocarbon, acid scavenger and antioxidant stabilizer"</p> <p>A62D1/00.</p> <p style="text-align: right;"><b>142655</b></p> <p>Composition is described that may be used for applications such as a fire extinguishing composition in fire extinguishing unit, refrigeration, and the like. This composition includes halocarbons and additives that may stabilize the composition in the presence of a metal, water, and/or air. For example, the composition comprising:</p> <p>(a) A bromofluorocarbon such as bromofluoroalkene (2-bromo-3,3,3-trifluoropropene);</p> <p>(b) Acid stabilizer (cyclohexene oxide or cyclopentene oxide); and</p> <p>(c) at least one antioxidant selected from the group consisting of: 2,5-di-tert-butyl-4-methoxyphenol; a C7-9 branched alkyl ester of</p>


		<p>3,5,-di-tert-butyl-4-hydroxycinnamic acid; and 1,2,5,6-diepoxyoctane.</p>
<p>340/ 2013</p>	<p>Phenex Pharmaceuticals AG. Germany.</p>	<p>" (trans)-3-(4-(3-(tert-Butyl)-5-(1-methylcyclopropyl)phenyl)-5-(cyclohexylmethyl)-1-methyl-1H-pyrrole-2-carboxamido)cyclobutanecarboxylic acid as Modulator for the Orphan Nuclear Receptor ROR Gamma"</p> <p>C07D207/34,C07D731/14,C07D249/10,C07D401/04 , C07D405/04, A61K31/40 &amp; A61P29/00.</p> <p style="text-align: right;"><b>142656</b></p> <p>The invention provides modulators for the orphan nuclear receptor ROR<math>\gamma</math>. Specifically, the present invention provides carboxamide containing cyclic compound of Formula (1) to Formula (5)</p> <div style="text-align: center;">  <p>(1)      (2)      (3)      (4)      (5)</p> </div> <p>wherein  R<sup>1</sup> is independently selected from C<sub>1-10</sub>-alkyl, C<sub>2-10</sub>-alkenyl, C<sub>2-10</sub>-alkynyl, C<sub>3-10</sub>-cycloalkyl, C<sub>3-10</sub>-heterocycloalkyl, C<sub>1-10</sub>-alkylene-C<sub>3-10</sub>-cycloalkyl, C<sub>1-10</sub>-alkylene-C<sub>3-10</sub>-heterocycloalkyl, C<sub>1-10</sub>-alkylene-(5-membered heteroaryl), SO<sub>2</sub>-C<sub>1-10</sub>-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from oxo, CN, OR<sup>11</sup>, O-C<sub>2-6</sub>-alkylene-OR<sup>11</sup>, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, halogen, CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, CONR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, COR<sup>11</sup>, SO<sub>x</sub>R<sup>11</sup>, SO<sub>3</sub>H, SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>COR<sup>11</sup>, NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, NR<sup>11</sup>-CO-NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>-SO<sub>2</sub>-NR<sup>11</sup>R<sup>12</sup>, C<sub>3-10</sub>-cycloalkyl, O-C<sub>3-10</sub>-cycloalkyl, C<sub>3-10</sub>-heterocycloalkyl, O-C<sub>3-10</sub>-heterocycloalkyl and N R<sup>11</sup> R<sup>12</sup>.  R<sup>2</sup> is R<sup>1</sup> or H;  or R<sup>1</sup> and R<sup>2</sup> when taken together with the nitrogen to which they are attached complete a 3-</p>






		<p>to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from halogen, oxo, CN, OR<sup>11</sup>, SO<sub>x</sub>R<sup>11</sup>, SO<sub>3</sub>H, NR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, SO<sub>2</sub>NR<sup>11</sup>R<sup>12</sup>, C<sub>0-6</sub>-alkylene-CO<sub>2</sub>R<sup>11</sup>, CONR<sup>11</sup>R<sup>12</sup>, CONR<sup>11</sup>SO<sub>2</sub>R<sup>11</sup>, COR<sup>11</sup>, NR<sup>11</sup>-CO-R<sup>11</sup>, NR<sup>11</sup>-CO-NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>-SO<sub>2</sub>-NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>R<sup>12</sup>, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, hydroxy-C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, O-C<sub>3-8</sub>-cycloalkyl, C<sub>3-8</sub>-heterocycloalkyl and O-C<sub>3-8</sub>-heterocycloalkyl, wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 4 substituents independently selected from halogen, C<sub>1-3</sub>-alkyl, halo-C<sub>1-3</sub>-alkyl, OH, O-C<sub>1-3</sub>-alkyl, O-halo-C<sub>1-3</sub>-alkyl, SO<sub>2</sub>-C<sub>1-3</sub>-alkyl, COOH and oxo;</p> <p>R<sup>3</sup> is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S, wherein aryl and heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, halo-C<sub>1-6</sub>-alkyl, OH, O-C<sub>1-6</sub>-alkyl, O-halo-C<sub>1-6</sub>-alkyl, C<sub>0-6</sub>-alkylene-C<sub>3-10</sub>-cycloalkyl, C<sub>0-6</sub>-alkylene-C<sub>3-10</sub>-heterocycloalkyl, C<sub>0-6</sub>-alkylene-(5- or 6-membered heteroaryl), C<sub>1-6</sub>-alkylene-O-R<sup>31</sup>, C<sub>0-6</sub>-alkylene-CN, C<sub>0-6</sub>-alkylene-N(R<sup>31</sup>)<sub>2</sub>, O-C<sub>3-10</sub>-cycloalkyl, O-C<sub>1-6</sub>-alkylene-O-R<sup>31</sup>, O-C<sub>3-10</sub>-heterocycloalkyl, C<sub>0-6</sub>-alkylene-COOR<sup>31</sup>, C<sub>0-6</sub>-alkylene-C(O)R<sup>31</sup>, C<sub>0-6</sub>-alkylene-C(O)N(R<sup>31</sup>)<sub>2</sub>, C<sub>0-6</sub>-alkylene-N(R<sup>31</sup>)C(O)R<sup>31</sup>, C<sub>0-6</sub>-alkylene-SO-R<sup>31</sup>, C<sub>0-6</sub>-alkylene-SO<sub>2</sub>-R<sup>31</sup>, C<sub>0-6</sub>-alkylene-SO<sub>2</sub>-N(R<sup>31</sup>)<sub>2</sub>, C<sub>0-6</sub>-alkylene-N(R<sup>31</sup>)SO<sub>2</sub>-R<sup>31</sup>, C<sub>0-6</sub>-alkylene-SO<sub>2</sub>-C<sub>3-10</sub>-heterocycloalkyl and C<sub>0-6</sub>-alkylene-SO<sub>2</sub>-C<sub>3-10</sub>-heterocycloalkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and the 5- or 6-membered heteroaryl is optionally substituted by 1 to 4 substituents independently selected from the group consisting of halogen, CN, C<sub>1-3</sub>-alkyl, halo-C<sub>1-3</sub>-alkyl, OH, oxo, =N-OR<sup>32</sup>, O-C<sub>1-3</sub>-alkyl and O-halo-C<sub>1-3</sub>-alkyl, or wherein two adjacent substituents completing a 3- to 8-membered saturated or partially</p>
--	--	--

		<p>unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 7 substituents independently selected from halogen, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, C<sub>3-6</sub>-heterocycloalkyl, oxo, =N-OR<sup>32</sup>, OH, O-C<sub>1-6</sub>-alkyl and O-halo-C<sub>1-6</sub>-alkyl;  R<sup>4</sup> is (CR<sup>8</sup>R<sup>9</sup>)R<sup>40</sup>, (C=O)R<sup>40</sup>, (C=O)NR<sup>13</sup>R<sup>14</sup>, O-R<sup>40</sup>, C<sub>3-10</sub>-cycloalkylidene-methyl, C<sub>3</sub>-cycloalkylene-R<sup>40</sup> or SO<sub>y</sub>-R<sup>7</sup>;  R<sup>5</sup> is H, C<sub>1-3</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl or halo-C<sub>1-3</sub>-alkyl,  wherein alkyl, cycloalkyl and haloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, O-C<sub>1-6</sub>-alkyl and O-halo-C<sub>1-6</sub>-alkyl;  R<sup>6</sup> is independently H, halogen, CN, C<sub>1-3</sub>-alkyl, C<sub>3-6</sub>-cycloalkyl, halo-C<sub>1-3</sub>-alkyl or CONHR<sup>61</sup>R<sup>62</sup>,  wherein alkyl, cycloalkyl and haloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, O-C<sub>1-6</sub>-alkyl and O-halo-C<sub>1-6</sub>-alkyl;  R<sup>7</sup> is C<sub>3-10</sub>-cycloalkyl or C<sub>3-10</sub>-heterocycloalkyl, wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C<sub>1-6</sub>-alkyl, O-halo-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl and 3 to 7-membered heterocycloalkyl;  R<sup>8</sup> is H, F, C<sub>1-3</sub>-alkyl, halo-C<sub>1-3</sub>-alkyl, OH, O-C<sub>1-3</sub>-alkyl or O-halo-C<sub>1-3</sub>-alkyl;  R<sup>9</sup> is H, F, C<sub>1-3</sub>-alkyl or halo-C<sub>1-3</sub>-alkyl;  R<sup>11</sup> is independently selected from H, C<sub>1-6</sub>-alkyl, C<sub>0-6</sub>-alkylene-C<sub>3-10</sub>-cycloalkyl and C<sub>0-6</sub>-alkylene-C<sub>3-10</sub>-heterocycloalkyl,  wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents selected from the group consisting of halogen, CN, OH, oxo, C<sub>1-3</sub>-alkyl, halo-C<sub>1-3</sub>-alkyl, O-C<sub>1-3</sub>-alkyl, O-halo-C<sub>1-3</sub>-alkyl, NH<sub>2</sub>, NH(C<sub>1-3</sub>-alkyl), N(C<sub>1-3</sub>-alkyl)<sub>2</sub>, C<sub>3-6</sub>-heterocycloalkyl, C<sub>3-6</sub>-cycloalkyl and SO<sub>2</sub>-C<sub>1-3</sub>-</p>
--	--	---

		<p>alkyl,          wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, OH, oxo, Me and CF<sub>3</sub>;          R<sup>12</sup> is independently selected from H, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl and C<sub>3-6</sub>-cycloalkyl;          R<sup>13</sup> and R<sup>14</sup> taken together with the nitrogen to which they are attached complete a 3- to 10-membered ring containing carbon atoms, wherein this ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C<sub>1-6</sub>-alkyl, O-halo-C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl and C<sub>3-6</sub>-cycloalkyl;          R<sup>31</sup> is independently selected from H, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, C<sub>0-6</sub>-alkylene-C<sub>3-8</sub>-cycloalkyl, C<sub>0-6</sub>-alkylene-C<sub>3-8</sub>-heterocycloalkyl, 5- or 6-membered heteroaryl and 6-membered aryl, wherein alkyl, alkylene, cyclolalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 6 substituents independently selected from halogen, CN, OH, oxo, =N-OR<sup>32</sup>, C<sub>1-3</sub>-alkyl, halo-C<sub>1-3</sub>-alkyl, O-C<sub>1-3</sub>-alkyl, O-halo-C<sub>1-3</sub>-alkyl and SO<sub>2</sub>-C<sub>1-3</sub>-alkyl;          and optionally when two R<sup>31</sup> are attached to a nitrogen atom, they may complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from fluoro, OH, oxo, C<sub>1-4</sub>-alkyl and halo-C<sub>1-4</sub>-alkyl;          R<sup>32</sup> is independently selected from H, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl and C<sub>3-6</sub>-cycloalkyl;          R<sup>40</sup> is C<sub>3-10</sub>-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C<sub>1-6</sub>-alkyl, O-halo C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkyl, halo-C<sub>1-6</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl and C<sub>3-8</sub>-heterocycloalkyl;          R<sup>61</sup> and R<sup>62</sup> are independently selected from the group consisting of H, C<sub>1-3</sub>-alkyl and halo-C<sub>1-3</sub>-alkyl;          x and y is independently selected from 0, 1 and 2;</p>
--	--	---

		<p>with the proviso that compound 5-(cyclopentylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide is excluded and compound of Formula (5), wherein R<sup>4</sup> is OR<sup>40</sup> are excluded.</p>
<p>475/ 2015</p>	<p>F. HOFFMANN-LA ROCHE AG Switzerland.</p>	<p>"2-OXA-5-AZABICYCLO [2.2.1 ]HEPTAN-3-YL COMPOUND"</p> <p>C07D491/06, A61K31/35, A61K31/407 &amp; A61P25/28.</p> <p style="text-align: right;"><b>142657</b></p> <p>The present invention relates to compound of formula</p> <div style="text-align: center;">  <p style="text-align: right;">I,</p> </div> <p>wherein L is a bond, —C(O)NH-, -NHC(O)-, -CH<sub>2</sub>NHC(O)-, CH<sub>2</sub>C(O)NH-, -CH<sub>2</sub>NH-, -NH- or -NHC(O)NH-; R<sup>1</sup> is hydrogen, lower alkyl, halogen, lower alkoxy-alkyl, lower alkoxy substituted by halogen, lower alkyl substituted by halogen or is phenyl or heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl or pyrazolyl, and wherein phenyl and heteroaryl are optionally substituted by one, two or three substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl or O-CH<sub>2</sub>-cycloalkyl; which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating</p>

		<p>disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.</p>
<p>683/2016</p>	<p>F. HOFFMANN-LA ROCHE AG Switzerland.</p>	<p>" INDOLIN-2-ONE COMPOUND"</p> <p>C07D401/14,C07D409/14,C07D403/14,A61K31/44, A61K31/506, A61P25/00 &amp; A61P25/18.</p> <p style="text-align: right;"><b>142658</b></p> <p>The present invention is concerned with indolin-2-one derivatives of general formula</p> <div style="text-align: center;">  <p style="text-align: right;">I</p> </div> <p>wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from</p> <div style="text-align: center;">  </div> <p>R<sup>1</sup> is S(O)<sub>2</sub> lower alkyl, S(O)<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, S(O)<sub>2</sub>cycloalkyl, S-lower alkyl or S(O)<sub>2</sub>-azetidinyll-yl; R<sup>4</sup> and R<sup>5</sup> are independently from each other hydrogen, lower alkyl or (CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>; or the group A-R<sup>1</sup> may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from</p>

		<div style="text-align: center;">  </div> <p> <math>R^2</math> is hydrogen or cycloalkyl;  <math>R^3</math> is methyl or halogen;  <math>n</math> is 1 or 2;  <math>X</math> is N, <math>N^+O^-</math> or CH;  --- the dotted line may be nothing or <math>-CH_2-</math>. </p>
--	--	--

**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>01/01/2018</u></b>			
1.	19087	Drinking Glass(Class-03)	Every Day Plastic Industry
<b><u>03/01/2018</u></b>			
2.	19088	Intelligent Glucose Meter (Class-03)	Sinocare Inc.,

**REGISTRATION OF DESIGNS**

The following designs have been registered.

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Applicant</b>
<b><u>03/01/2018</u></b>			
1.	18044	Sharpener (Class-03)	ORO Industries
2.	18045	Sharpener (Class-03)	ORO Industries
3.	18502	Dinner Set (Class-03)	Asif Zubair & Co.
4.	18503	Hot Pot (Class-03)	Asif Zubair & Co.
5.	18777	Set of Cloth (Class-13)	SS Fashion Resources
6.	18778	Set of Cloth (Class-13)	SS Fashion Resources
7.	18779	Set of Cloth (Class-13)	SS Fashion Resources
8.	18780	Set of Cloth (Class-13)	SS Fashion Resources
9.	18781	Set of Cloth (Class-13)	SS Fashion Resources
10.	18782	Set of Cloth (Class-13)	SS Fashion Resources



**(Dr. Muhammad Fayyaz Ahmad)**  
 Controller of Patents  
 & Registrar of Designs  
 Ph: 99230591